Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial

Overview of attention for article published in Lancet Oncology, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (97th percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 5 news outlets
blogs: 1 blog

twitter: 96 X users
guideline: 1 clinical guideline source

Readers on

mendeley: 97 Mendeley

So far, Altmetric has seen 112 X posts from 96 X users, with an upper bound of 585,496 followers.

RT @tuttsakhil: Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a…

Trastuzumab with trimodality treatment for oesophageal adenocarcinoma with HER2 overexpression (NRG Oncology/RTOG 1010): a multicentre, randomised, phase 3 trial - 👉Addition of trastuzumab to CROSS doesn't improve outcomes in esophageal adenocarcinoma …

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 108 additional X posts.